Hepatitis C and COVID-19: What Clinicians in Rural and Underserved Areas Need to Know

Activity Details
  • Credit Amounts:
    • CME: 0.50
    • Other: 0.50
  • Cost: Free
  • Release: Jul 15, 2020
  • Expires: Jan 15, 2021
  • Estimated Time to Complete:
    30 Minutes
  • System Requirements:
  • Average User Rating:
    ( Ratings)

How to Obtain Credit
In order to successfully complete this activity, you are required to listen to the entire program and complete the program evaluation. A certificate of credit will be available for immediate download.

Resources (mentioned during program)

Activity Transcript (select this link to view or download)

 

Faculty

Nancy S.  Reau Nancy S. Reau, MD (Program Chair)
Richard B. Capps Chair of Hepatology
Professor, Department of Internal Medicine
Division of Digestive Diseases and Nutrition
Rush Medical College
Chief, Section of Hepatology
Associate Director of Organ Transplantation
Rush University Medical Center
Chicago, IL

Barbara P. Yawn Barbara P. Yawn, MD, MSc, MPH (Moderator)
Chief Science Officer, COPD Foundation
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

Needs Statement

In the United States, approximately 2.4 million individuals are living with hepatitis C virus (HCV). Compared to a decade ago, there are now more than 3 times the number of acute cases, particularly among young, white injection drug users who live in rural areas. However, an estimated 1 million Americans are not aware that they are infected. As a result of the changing epidemiology and the availability of highly effective treatments, screening guidelines for HCV were recently updated. It is therefore critical for primary care clinicians to be aware of recent recommendations for universal screening. Additionally, with the advent of new, highly effective direct-acting antiviral therapy and the simplicity of these newer regimens, primary care clinicians can play a significant role in ensuring patients have access to treatment. Recently, the novel coronavirus (COVID-19) has introduced various challenges in providing routine care to patients with or at risk for HCV. In this activity, experts in the field review best practices for screening, treatment, and monitoring of HCV infection in the COVID-19 era. Strategies for overcoming barriers to HCV care in rural and underserved areas will also be discussed.

Please note that any data, information, and guidance presented in the activity are current as of the recording on July 7, 2020 and are subject to change.

 

Target Audience

This activity is designed specifically for primary care clinicians practicing in rural and underserved areas.

 

Objectives

Upon completion of this activity, participants should be better able to:

  • Apply current guidelines for age- and risk-based HCV screening
  • Implement effective follow-up and counseling for patients with confirmed diagnosis of HCV infection
  • Describe currently available and emerging treatment options for HCV infection
  • Incorporate evidence-based treatment guidelines into the effective management of patients with HCV infection

 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and RME Collaborative. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Faculty Disclosure

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Nursing Continuing Professional Development (NCPD) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

FACULTY
Nancy S. Reau, MD, has disclosed the following relationships: consultant for AbbVie, Inc. and Gilead Sciences, Inc.; contracted research support from Gilead Sciences, Inc.

Barbara P. Yawn, MD, MSc, MPH, has no relevant financial relationships to disclose.

Faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.

PLANNING COMMITTEE
Robert Lowe, MD, CME Course Director, Boston University School of Medicine is a consultant for GI Reviewers.

The following planning committee members for this activity have no relevant financial relationships to disclose:

Michael Burk, Program Manager, Boston University School of Medicine, CME
Erica Rusie, PharmD, Scientific Director, Scientific Affairs, Talem Health, LLC

 

Acknowledgment

This activity is supported by an educational grant from AbbVie Inc.

 

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTHCARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY OR TALEM HEALTH BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

©RME Collaborative, a division of Talem Health, LLC 2020. All Rights Reserved.

 

Contact Us

For questions regarding this CME activity, please contact:
RME Collaborative by phone, 800-913-9370 or email, info@talemhealth.com